Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
11.45
+1.60 (16.24%)
At close: Jun 26, 2026, 4:00 PM EDT
11.55
+0.10 (0.87%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Eikon Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Eikon Therapeutics stock have an average target of 23.75, with a low estimate of 5.00 and a high estimate of 32. The average target predicts an increase of 107.42% from the current stock price of 11.45.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Eikon Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|---|
| Strong Buy | 0 | 3 | 3 | 3 |
| Buy | 0 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 |
| Total | 1 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $34 → $32 | Buy | Reiterates | $34 → $32 | +179.48% | Jun 3, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 1, 2026 |
| Wedbush | Wedbush | Sell Maintains $7 → $5 | Sell | Maintains | $7 → $5 | -56.33% | May 12, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Initiates $26 | Buy | Initiates | $26 | +127.07% | Mar 2, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $32 | Buy | Maintains | $32 | +179.48% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-6.35
from -115.29
EPS Next Year
-6.19
from -6.35
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -6.35 | -6.19 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.